We provide commercially focused, creative advice on obtaining, enforcing and exploiting intellectual property rights including patents, trade marks and designs to a wide range of clients who enjoy our straight forward approach and flexible working practices.
From its small beginnings in 1867, Mewburn Ellis has grown into a vibrant, outward-looking partnership with innovation at its core. As science and technology continue to transform the way we live, we look forward to a future as positive and successful as our past.
It's business as usual for Mewburn Ellis despite the decision for the UK to end its membership of the EU. We consider the effect of the decision on intellectual property.
Our experience advising a wide range of clients, from UK-based component manufacturers to multi-national vehicle manufacturers, means we can help you develop an appropriate IP strategy to meet your business needs.
With a medtech team including patent attorneys drawn from all technical disciplines, you can rest assured that you will be working with a specialist that truly understands your technology.
The worldwide recognition achieved by our large pharmaceutical team will give you the confidence that your commercially valuable intellectual property is in the best hands.
t: +44 (0)20 7776 5300
t: +44 (0)117 945 1234
t: +44 (0)1223 420383
t: +44 (0)161 247 7722
F-star, a biopharmaceutical company developing bispecific antibody immuno-oncology products, has announced a new partnership with a leading science and technology company. This new strategic collaboration will focus on the development and commercialisation of five bispecific immuno-oncology antibodies.
On 12 July, 2017 an important judgement was handed down by the UK Supreme Court in the case of Eli Lilly v Actavis UK. The reasoning in the decision is significant for UK law in two legal areas: file wrapper estoppel and doctrine of equivalents.